Anti-Tumor
Showing 9976 - 10000 of >10,000
Advanced Malignant Solid Tumor, RAS Mutation, Lung Cancer Trial in United States (RSC-1255 Dose Escalation, RSC-1255 Dose
Recruiting
- Advanced Malignant Solid Neoplasm
- +5 more
- RSC-1255 Dose Escalation
- RSC-1255 Dose Expansion
-
Los Angeles, California
- +5 more
Oct 24, 2022
Anesthesia Trial (PENG Block, Control Group)
Not yet recruiting
- Anesthesia
- PENG Block
- Control Group
- (no location specified)
Jun 15, 2023
HIV, AIDS, Immunologic Deficiency Syndrome, Acquired Trial in Boston (Ad26.Mos4.HIV, MVA-BN-HIV, PGT121)
Recruiting
- HIV
- +4 more
- Ad26.Mos4.HIV
- +4 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Apr 18, 2022
Uveitis Trial in Worldwide (Adalimumab (ADA), Conventional immunosuppression (CON))
Recruiting
- Uveitis
- Adalimumab (ADA)
- Conventional immunosuppression (CON)
-
Los Angeles, California
- +27 more
Jun 16, 2022
Cancer Trial in Shenzhen (No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic
Recruiting
- Cancer
- No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.
-
Shenzhen, Guangdong, ChinaUHongKongShenzhen
Sep 20, 2021
Prostate Cancer, Prostate Adenocarcinoma Trial in Miami (Lattice Extreme Ablative Dose Radiation Therapy, Standard IMRT)
Completed
- Prostate Cancer
- Prostate Adenocarcinoma
- Lattice Extreme Ablative Dose Radiation Therapy
- Standard IMRT
-
Miami, FloridaUniversity of Miami
Jul 11, 2021
Colorectal Cancer, Non Small Cell Lung Cancer Trial in France (Liquid biopsy)
Recruiting
- Colorectal Cancer
- Non Small Cell Lung Cancer
- Liquid biopsy
-
Bayonne, France
- +5 more
Feb 1, 2022
Acute Myeloid Leukemia Trial in Wuxi (Anti-CD33/CLL1 CAR-NK Cells)
Recruiting
- Acute Myeloid Leukemia
- Anti-CD33/CLL1 CAR-NK Cells
-
Wuxi, Jiangsu, ChinaWuxi People's Hospital
Jan 18, 2022
Metastatic Urothelial Carcinoma Trial (Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring)
Not yet recruiting
- Metastatic Urothelial Carcinoma
- Pembrolizumab (200mg)
- +2 more
- (no location specified)
Sep 18, 2023
Leukemia Trial in Bronx (deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins)
Completed
- Leukemia
- deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
-
Bronx, New YorkAlbert Einstein Cancer Center at Albert Einstein College of Medi
Apr 9, 2021
Pancreatic Adenocarcinoma, Pancreas Cancer Trial in Roma, Rome (EUS-guided laser ablation)
Terminated
- Pancreatic Adenocarcinoma
- Pancreas Cancer
- EUS-guided laser ablation
-
Roma, RM, Italy
- +1 more
Feb 10, 2022
Medical Marijuana in Pediatric Central Nervous System Tumor
Active, not recruiting
- Central Nervous System Tumor
- +2 more
-
Aurora, ColoradoChilsdren's Hospital Colorado
Oct 14, 2022
Brain Tumor Trial in Phoenix (MRI)
Recruiting
- Brain Tumor
- MRI
-
Phoenix, ArizonaSt. Joseph's Hospital and Medical Center
Sep 20, 2021
Desmoplastic Melanoma Trial in United States (Pembrolizumab, Therapeutic Conventional Surgery)
Active, not recruiting
- Desmoplastic Melanoma
- Pembrolizumab
- Therapeutic Conventional Surgery
-
Fairbanks, Alaska
- +282 more
Jun 28, 2022
Bladder Tumor Trial in Istanbul (En Bloc Resection, Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar))
Recruiting
- Bladder Neoplasm
- En Bloc Resection
- Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
-
Istanbul, Bagcilar, Turkey
- +1 more
Apr 11, 2022
Solid Tumors and Hematologic Malignancy Trial in Australia (INCSHR01210 injection)
Completed
- Solid Tumors and Hematologic Malignancy
- INCSHR01210 injection
-
Heidelberg, Victoria, Australia
- +4 more
Sep 26, 2019
Malignant Peripheral Nerve Sheath Tumor Development in
Active, not recruiting
- Neurofibromatosis 1
- Peripheral Nerve Neoplasms, Malignant
-
Bethesda, MarylandNational Cancer Institute (NCI)
Jul 6, 2022
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B Trial run by the NCI
Completed
- Medullary Thyroid Carcinoma
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 1, 2020
Head and Neck Squamous Cell Cancer Trial in Philadelphia (INO-3112, CELLECTRA™-5P)
Completed
- Head and Neck Squamous Cell Cancer
- INO-3112
- CELLECTRA™-5P
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Jan 4, 2021
Gastro-enteropancreatic Neuroendocrine Tumor Trial (Pasireotide, Diazoxide)
Withdrawn
- Gastro-enteropancreatic Neuroendocrine Tumor
- (no location specified)
Feb 17, 2022
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial
Active, not recruiting
- Recurrent Bladder Urothelial Carcinoma
- +3 more
-
Daphne, Alabama
- +271 more
Jul 20, 2022
Epidermoid Carcinoma, Anus Trial in France (radiochemo, Panitumumab)
Completed
- Epidermoid Carcinoma
- Anus
-
Bordeaux, France
- +14 more
Mar 23, 2022